XOMA (NASDAQ:XOMA) Downgraded by TheStreet to “C+”

TheStreet cut shares of XOMA (NASDAQ:XOMAGet Rating) from a b- rating to a c+ rating in a research report released on Tuesday, TheStreetRatingsTable reports.

XOMA has been the topic of several other research reports. StockNews.com downgraded shares of XOMA from a buy rating to a hold rating in a research note on Friday, April 22nd. HC Wainwright reaffirmed a buy rating and issued a $69.00 price target on shares of XOMA in a research note on Monday, May 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, XOMA has an average rating of Hold and an average price target of $49.00.

XOMA stock opened at $17.17 on Tuesday. The firm has a 50-day moving average price of $23.00 and a 200-day moving average price of $22.43. The firm has a market capitalization of $196.10 million, a PE ratio of 32.40 and a beta of 1.09. XOMA has a 12-month low of $16.96 and a 12-month high of $39.02.

XOMA (NASDAQ:XOMAGet Rating) last released its earnings results on Thursday, May 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.02. The firm had revenue of $3.11 million during the quarter, compared to analyst estimates of $3.56 million. XOMA had a net margin of 27.35% and a return on equity of 8.77%. Equities analysts forecast that XOMA will post -0.33 EPS for the current year.

In other news, CFO Thomas M. Burns sold 2,339 shares of XOMA stock in a transaction that occurred on Tuesday, March 22nd. The shares were sold at an average price of $30.02, for a total value of $70,216.78. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO James R. Neal sold 1,111 shares of XOMA stock in a transaction that occurred on Wednesday, March 23rd. The stock was sold at an average price of $30.02, for a total transaction of $33,352.22. The disclosure for this sale can be found here. Insiders have sold a total of 53,450 shares of company stock worth $1,553,569 in the last three months. Insiders own 10.90% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Citigroup Inc. lifted its stake in XOMA by 118.0% during the 4th quarter. Citigroup Inc. now owns 1,528 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 827 shares during the period. BNP Paribas Arbitrage SA lifted its stake in XOMA by 138.5% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 1,436 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 834 shares during the period. Barclays PLC lifted its stake in XOMA by 222.0% during the 3rd quarter. Barclays PLC now owns 2,463 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 1,698 shares during the period. Morgan Stanley lifted its stake in XOMA by 181.6% during the 2nd quarter. Morgan Stanley now owns 2,630 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 1,696 shares during the period. Finally, UBS Group AG lifted its stake in XOMA by 23.5% during the 1st quarter. UBS Group AG now owns 3,632 shares of the biotechnology company’s stock valued at $101,000 after acquiring an additional 691 shares during the period. Institutional investors and hedge funds own 56.11% of the company’s stock.

XOMA Company Profile (Get Rating)

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.

Recommended Stories

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.